Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. Lantheus ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

On January 28, the company announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal, which includes an upfront payment of $250 million and up to $752.5 million in ...

“With Evergreen's manufacturing and development capabilities, we become fully integrated. We are pleased to welcome Evergreen's talented team to Lantheus and are confident that their expertise in ...

BBJ's Don Seiffert has the details. Lantheus Holdings Inc. is acquiring Evergreen Theragnostics Inc., a clinical-stage radiopharmaceutical company, in a deal worth about $1B. Beauty brands ...

Last week, Lantheus announced plans to acquire clinical stage radiopharma CDMO Evergreen Theragnostics for an upfront payment of $250m, with the potential for an additional $752.5m in milestone ...